Table 2.
Univariable and multivariable analysis estimates represent the difference in MVX scores per unit of continuous variables or the presence (yes/no) of categorical variables
| UNIVARIABLE | MULTIVARIABLE | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLINICAL TRIAL | COMMUNITY COHORT | CLINICAL TRIAL | COMMUNITY COHORT | |||||||||
| Variable | β | 95% CI | p-value | β | 95% CI | p-value | β | 95% CI | p-value | β | 95% CI | p-value |
| Age | 0.17 | -0.12, 0.46 | 0.323 | 0.09 | -0.01, 0.19 | 0.081 | 0.09 | -0.19, 0.38 | 0.516 | -0.06 | -0.16, 0.04 | 0.266 |
| Male sex | 15.67 | 5.99, 25.35 | 0.002 | 1.04 | -1.65, 3.7 | 0.452 | 15.32 | 5.14, 25.51 | 0.036 | 1.97 | -0.42, 4.36 | 0.106 |
| Obesity | -0.57 | -5.74, 4.60 | 0.829 | -3.30 | -5.81, -0.79 | 0.010 | -1.40 | -6.50, 3.70 | 0.587 | -1.30 | -3.78, 1.18 | 0.303 |
| Smoking | -1.11 | -6.62, 4.40 | 0.694 | 1.99 | -0.71, 4.69 | 0.150 | ||||||
| Hypertension | 3.41 | -3.47, 10.29 | 0.333 | -1.25 | -5.48, 2.98 | 0.564 | ||||||
| Hyperlipidemia | 9.82 | 0.45, 19.19 | 0.04 | -3.96 | -8.80, 0.88 | 0.110 | 8.78 | -0.48, 18.05 | 0.629 | -3.15 | -7.47, 1.15 | 0.151 |
| Diabetes | 4.32 | -1.21, 9.85 | 0.129 | -0.10 | -2.59, 2.39 | 0.936 | ||||||
| Myocardial Infarction | -5.48 | -17.34, 6.38 | 0.368 | 1.98 | -0.55, 4.51 | 0.126 | ||||||
| Stroke | 4.64 | -3.96, 13.24 | 0.293 | -2.50 | -5.20, 0.20 | 0.070 | ||||||
| Atrial Fibrillation | 0.07 | -5.48, 5.62 | 0.981 | 1.77 | -0.82, 4.36 | 0.183 | ||||||
| Ejection fraction | 0.17 | -0.26, 0.60 | 0.443 | -0.11 | -0.27, 0.05 | 0.198 | ||||||
| NYHA III/IV | 3.61 | -3.62, 10.84 | 0.331 | 2.15 | -0.77, 5.07 | 0.150 | ||||||
| NTproBNP α | -0.20 | 1.77, 1.37 | 0.805 | 4.14 | 3.26, 5.02 | < 0.001 | 0.19 | -1.43, 1.81 | 0.818 | 4.18 | 3.24, 5.12 | < 0.001 |
Data are reported as beta coefficients (β) and 95% confidence intervals; NYHA: New York Heart Association; NTproBNP: N-terminal pro-B type natriuretic peptide (pg/ml). αLog2-transformed. Significant p-values are in bold format